FOR AUTHORS

Submitting an article

To read about how to prepare your article, please click on Instructions for Authors. If you are ready to submit an article, please click on Online Submission.

Benefits of publishing with Molecular Therapy

Molecular Therapy is published in partnership with Nature Publishing Group (NPG), which uses pioneering technologies, innovative formats and world class production to provide premium information for scientific researchers in the public and private sectors, government agencies and educators.

A key strength of NPG is its close relationship with the scientific community. By working closely with scientists, listening to what they say, and always placing emphasis on quality rather than quantity, NPG is the leading scientific publisher at finding innovative solutions to scientists' information needs, both for the Nature-branded publications and those published on behalf of society partners, including American Society of Gene & Cell Therapy.

Publishing with Molecular Therapy and NPG provides an author with a wide range of benefits:

Copyright and license to publish

The ASGCT does not require authors of original research papers to assign copyright of their published contributions. Authors grant the ASGCT an exclusive license to publish, in return for which they can re-use their papers in their future printed work. NPG's author license page provides details of the policy and a sample form. Authors are encouraged to submit their version of the accepted, peer-reviewed manuscript to their funding body's archive, for public release six months after publication. In addition, authors are encouraged to archive their version of the manuscript in their institution's repositories (as well as on their personal web sites), also six months after the original publication. Authors should cite the publication reference and doi number on any deposited version, and provide a link from it to the published article on the NPG website. This policy complements the policies of the US National Institutes of Health, the Wellcome Trust and other research funding bodies around the world. NPG recognizes the efforts of funding bodies to increase access of the research they fund, and strongly encourages authors to participate in such efforts.

Online presence - reducing publication times

Molecular Therapy uses an online submission system, which allows authors to submit papers via the Web. Speeding up the submission and reviewing process, this system also allows you to view the status of your paper online.

Advance online publication (AOP)

New articles in Molecular Therapy, as in all NPG journals, are published weekly online ahead of the archival print issue, ensuring the research is made publicly available and can be cited as soon as possible after acceptance for publication. The online publication is identical to the printed version and is not a preliminary, unedited version. AOP articles are the definitive versions of the paper and can be cited immediately using the Digital Object Identifier (DOI). Visit the Advance online publication page to learn more about AOP.

Supplementary online material

Authors are invited to submit additional supporting material such as data sets or video for publication in the online version of the journal. Online supplementary material makes the most of the Web as a delivery platform and can often give articles greater depth, making them more useful to readers.

Quality

Authors who choose to publish in any NPG journal can be assured that its staff's publishing, editorial and production skills are committed to maintaining the highest possible quality and standards.

Exposure - widest possible readership

All NPG journals, including Molecular Therapy, are available online via site licenses to academic, corporate, government institutions and consortia. Journals are available to members of these institutions at the click of a mouse, adding speed and visibility to authors' research papers.

Regular free e-mail alerts

Content published in Molecular Therapy has the potential to reach scientists around the world who have signed up for NPG's free table of contents e-alerts, ensuring additional exposure to authors. These e-alerts allow recipients to click through to the full article if they subscribe to the journal or work at an institution with a site license. Other readers may click through to the article's abstract.

Focused subject areas on nature.com

From immunology and physics to genetics and materials, NPG offers its readers subject-specific areas which provide a focus on content and news pertaining to a particular field. These subject areas are updated monthly.

Abstracting and indexing

Molecular Therapy is included in the leading abstracting and indexing services including ISI, MEDLINE, EMBASE and BIOSIS. Extensive reference linking to MEDLINE, ISI, Chemport and others via services such as Crossref and DOI numbers provide seamless online linking between articles and databases.

Media coverage

The Nature press office provides information about exceptionally interesting papers published throughout NPG. More than 2,000 journalists and media organizations worldwide subscribe to the press service, ensuring that papers receive maximum exposure in the world's most important media channels including newspapers, magazines, radio and television.

Extending science further - global collaborations

NPG and Molecular Therapy support some projects aimed at making current research available to a broader community of scientists and practitioners.

All NPG journals, including Molecular Therapy, are in WHO's HINARI (Health InterNetwork Access to Research Initiative) program, which provides free access to public institutions in developing countries.

MT Open & Self Archiving

• Authors are encouraged to submit the author's version of the accepted paper (the unedited manuscript) to their funding body's archive, for public release six months after publication. In addition, authors are encouraged to archive this version of the manuscript in their institution's repositories and on their personal websites, also six months after the original publication.
• Authors of research articles can also opt to pay a one off fee of £2,000 / $3,000 / €2,400 (+VAT where applicable) for their accepted articles to be made freely available online immediately on publication. By paying this fee authors are also permitted to post the final, published PDF of their article on a web site, institutional repository or other free public server, immediately on publication. Open access articles will be designated by the ^MTOpen logo in both the print and online editions of the journal and will be freely accessible via PubMed Central immediately after publication. Please see the FAQ's for further details or click here to download the PAYMENT FORM.
• All Molecular Therapy articles will be deposited to PubMed Central upon final publication to be made public 12 months after publication, except for Open Access articles which will be freely accessible on PubMed Central immediately following publication.
• In this regard, Molecular Therapy is fully compliant with the requirements of the major funding bodies worldwide with respect to open access publishing